From immune checkpoints to cytokines, viral antigens to amyloids — our in silico platform engineers monoclonals, bispecifics and nanobodies on any target with a 3D model. Phase-I-ready assets, not just binders.
Our platform is not confined to one therapeutic area. Each family leads to a structured set of targets, antibodies and case studies.
Six high-priority target classes, 15 targets engineered on the platform.
Our 6-step workflow runs on top of every target in this library.
Our platform handles any target with an available 3D model. Tell us about your project and we’ll come back with a feasibility note.
Each target page provides in-depth scientific analysis, engineering approach, clinical landscape, and the MAbSilico database profile. Click any card to explore.
More infectious disease targets coming soon — request a target
IL-4, IL-5, IL-13, IL-33 targets in preparation — request a target
VEGF-C, PDGFR, HER2 targets in preparation — request a target